The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...
University of Mississippi researchers have discovered how a compound found in cannabis might be used to mitigate the negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback